drugset / Trial / NCT03681561
Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/2
Recruiting
54 enrolled
Veronika Bachanova
Bristol-Myers Squibb · collabIncyte Corporation · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I/II, multicenter, open-label, dose escalation/dose-expansion study to evaluate the tolerability, safety, and the maximum tolerated dose (MTD) of ruxolitinib when given with fixed dose nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma (cHL).
Timeline
- Start
- 2018-09-13
- Primary completion
- 2026-09
- Completion
- 2027-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ruxolitinib | Small molecule | 10 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 15 mg | Oral |
| Subject | Ruxolitinib | Small molecule | 20 mg | Oral |
| Background | Nivolumab | Monoclonal antibody | 480 mg | Intravenous |